

Lucence Diagnostics, NCCS to improve Cancer Genetic Testing

27 July 2018 | News

NCCS will contribute its database of genomic variants and its expertise in classifying those variants for clinical use.



Lucence Diagnostics will be partnering with the National Cancer Centre Singapore (NCCS) on a study to improve genetic testing for breast and gynecological cancers in Asian women.

As part of the collaboration, NCCS will contribute its database of genomic variants and its expertise in classifying those variants for clinical use, and Lucence will contribute its own expertise in DNA sequencing and genomic data analysis.

Lucence is planning to collect blood samples from 300 patients with a personal or family history of breast and gynecological cancer, or early onset breast cancer. After sample extraction, researchers will use next-generation sequencing to identify genetic variants linked to cancer risks. NCCS will then build a database of hereditary breast and gynecological cancers mutations in Asian women across all ethnicities — including information from its own database, for clinical use.

Lucence and NCCS are also aiming to use the data to develop better services for early detection and prevention among women who are at high risk due to family history.

In addition to partnering with NCCS, Lucence is collaborating with Bangkok Molecular Genetics to distribute the firm's bloodbased cancer diagnosis and screening assays in Thailand. Lucence is also working with Singapore's Quest Laboratories to offer the blood-based cancer diagnostic assays developed by Lucence for Quest Lab's customers in the region.